Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03093116
Title A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Turning Point Therapeutics, Inc.
Indications

Advanced Solid Tumor

lung non-small cell carcinoma

Therapies

Repotrectinib

Age Groups: child | senior | adult
Covered Countries USA | CAN

Additional content available in CKB BOOST